20 years after the Women's Health Initiative (WHI), women are still concerned about the risks of hormone therapy. Dr. Holly L. Thacker discusses how hormone therapy is still the most effective treatment for menopause symptoms, especially hot flashes and night sweats.

Dr. Sandra Darling shares 6 healthy lifestyle tips to stimulate and support the brain and help lower the risk of Alzheimer's disease and other types of dementia.

Speaking of Women's Health guest columnist, Cheryl Taylor RNFA at Cleveland Clinic, shares tips on how women can prepare for and recover from hip and knee replacement surgeries.

The U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. This marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata. Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its…

Speaking of Women's Health is proud to be awarded a Digital Health Award for their HerDesire.net educational initiative on low sex drive. the awards were judged by more than 100 experts, with over 1,000 entries, recognizing the BEST in digital health resources.

Dr. Irina Todorov discusses how human connection is important for one's health.

Speaking of Women's Health guest columnist Dr. Jessica Ruff shares how acupuncture can help reduce headaches.

Scientists still may not know the exact cause of fibromyalgia, but that hasn’t stopped them from developing treatments for the chronic pain associated with the condition. For years, all of those therapeutics have been of the pharmacological variety, with three drugs approved by the FDA since 2007. Now, however, patients will have a drug-free alternative to treat their fibromyalgia, as the agency issued a de novo clearance for a wearable neuromodulation system from NeuroMetrix designed to ease…

The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Mounjaro is a…

The American Heart Association published a 2020 scientific statement on cardiovascular disease risk for women transitioning through or experiencing menopause. The report reflects scientific evidence on menopause and cardiovascular risks, and this article reviews the statement with a focus on what is new and what is clinically important for healthcare providers treating this patient population.

On the 20th anniversary of the now infamous Women’s Health Initiative (WHI) study that brought the field of Hormone Replacement Therapy (HRT) to its knees, it is only fitting that we revisit the study and use science-backed information to emphasize the true outcome of the findings. Especially when two decades later women are still impacted by the aftershocks. Join Dr. Holly L. Thacker and Dr. Alexa Fiffick from the Cleveland Clinic's Center for Specialized Women’s Health, as they address the…

Dr. Alexa N. Fiffick discusses why headaches are more common in women. Two of the most common headache conditions are cervicogenic headache and migraine.

Dr. Holly L. Thacker shares seven ways women can help prevent osteoporosis and have strong, healthy bones.

Twenty years ago, the National Institutes of Health abruptly terminated research on the effect of hormone therapy on postmenopausal women. The decision resulted in a cascade of harm to millions who have undergone menopause in the United States. And it remains uncorrected two decades later. More than 1 billion people worldwide will be in menopause by 2025. Today, there are 55 million in the United States alone, nearly 75 percent of whom report not receiving support or treatment for its effects.…

The U.S. Food and Drug Administration approved a 0.5 mg/100 mg dose of TherapeuticsMD Inc.'s  Bijuva hormone therapy. This low-dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause, is 0.5 milligrams (mg) of estradiol and 100 mg of progesterone (0.5/100mg). In 2018, the FDA approved Bijuva for the treatment of moderate to severe vasomotor symptoms of menopause at the 1mg of estradiol and 100 mg of progesterone (1/100 mg) dose.To learn…

Dr. Tiffany Cochran discusses why dry eye disease is so common among midlife women and what women can do to treat dry eyes.

Over twenty years ago, the Women’s Health Initiative (WHI) study, which randomized women to receive either hormone therapy or a placebo, set out to assess the benefits and risks of hormone therapy. In 2002, the WHI study was abruptly halted because the researchers found that women taking a combination of estrogen and progestin had an increased risk of breast cancer, heart attacks, stroke, and blood clots. Headlines blasted the news that hormone therapy was unsafe, and the use of hormone therapy…

Speaking of Women's Health guest columnist Dr. Sandra Darling shares one simple dietary change that can improve memory and other brain functions.

During the past 2 decades, Endocrine Today has reported on the latest developments in hormone therapy for symptoms associated with menopause. For its 20th year, the publication is taking a look back. Twenty years ago, findings from a pivotal study dramatically changed the public’s perception — as well as that of some health care providers — surrounding menopausal HT. According to the timing hypothesis, HT is safer for younger women who initiate it closer to the start of menopause and most…

Pregnancy, long reproductive span, and older age at menopause are associated with a lower risk of dementia in women, according to a recent study. Inversely, hysterectomy, younger age of first birth, and younger or older than average age at first period were associated with greater dementia risk. The study suggests that reproductive and hormonal factors may be involved in dementia risk, but observed a similar association between the number of children and dementia risk in women and men,…